ArticleFrontiers in oncology2023

Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients.

Lisa Salvatore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.